相关实验视频

Updated: Jan 9, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

萨尔维阿诺酸B:一个有前途的心脏保护剂

Yingchun Shao¹, Li Zhai¹, Shan Jiang¹

¹Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.

Frontiers in immunology

|December 8, 2025

概括

来自Salvia miltiorrhiza的Salvianolic acid B (SalB) 通过多种机制显示出对心血管疾病 (CVD) 的显著心脏保护作用. 本综述巩固了支持SalB作为CVD现代治疗药物的研究.

科学领域:

药理学药理学是指药理学的学科.
传统中国医药传统中国医药
心血管研究研究心血管研究

背景情况:

桑 (Salvia miltiorrhiza) 是中国传统医学中用于治疗心血管疾病 (CVD) 的关键草本.
沙尔维阿诺酸B (SalB) 是主要的生物活性化合物,具有对心血管疾病的治疗潜力.
目前关于SalB对心血管疾病的研究是分散的,需要进行全面的审查.

研究的目的:

在心血管疾病 (CVD) 的背景下,系统地审查和巩固目前关于沙尔维阿诺酸B (SalB) 的研究.
分析SalB的来源,药理机制,疗效,兼容性和剂量形式.
利用临床前和临床数据评估SalB的安全性和有效性,以指导其作为现代心血管疾病治疗方法的发展.

主要方法:

对SalB和CVD进行的临床前和临床研究的系统文献综述.
对药理学机制的分析,包括抗氧化,抗炎,自诱导,内皮功能,抗纤维和血液学效应.
整合数据以评估安全性和有效性概况.

主要成果:

萨尔B表现出多种心脏保护机制,包括抗氧化,抗炎和抗纤维活性.
证据支持SalB在改善内皮功能和血液病学的有效性.
临床前和临床数据表明SalB在心血管疾病管理中的安全性和有效性概况有利.

结论:

沙尔维阿诺酸B (SalB) 是心血管疾病 (CVD) 的有前途的治疗剂,因为它具有多方面的心脏保护作用.
需要进一步的研究和优化SalB的应用,以促进其转变为主流的CVD药物.
这一综述为未来的研究和SalB用于心血管健康的临床转化提供了基础.

关键词:

在CVD中,CVD是非常重要的.心血管疾病心血管疾病聚醇是一种多醇.盐酸乙乙醇酸的使用方法信号通道是指信号通道.

更多相关视频

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...